Literature DB >> 25519165

Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.

Alfonso Segarra Medrano1, Elias Jatem Escalante, Clara Carnicer Cáceres, Irene Agraz Pamplona, Maria Teresa Salcedo Allende, Natalia Ramos Terrades, Naiara Valtierra Carmeno, Elena Ostos Roldán, Karla Viviana Arredondo Agudelo, Juliana Jaramillo Vasquez.   

Abstract

CONTEXT: The dynamics of anti-phospholipase A2 antibody titers during treatment could predict clinical responses in patients with membranous nephropathy.
OBJECTIVES: We analyzed the predictive value of the dynamics of these antibodies on clinical responses.
MATERIALS AND METHODS: The serum antibody levels were measured before and during treatment in 79 patients with anti-phospholipase A2 receptor antibody membranous nephropathy treated with two different immunosuppression regimens
RESULTS: In both groups of patients, the relative reduction in antibody titers at 3 and 6 months preceded and predicted the clinical responses.
CONCLUSIONS: Antibody titer dynamics was useful for predicting clinical responses.

Entities:  

Keywords:  Cyclophospamide; membranous nephropathy; renal disease; rituximab; type M phospholipase A2 antibodies

Mesh:

Substances:

Year:  2014        PMID: 25519165     DOI: 10.3109/1354750X.2014.993708

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  13 in total

Review 1.  A Proposal for a Serology-Based Approach to Membranous Nephropathy.

Authors:  An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 10.121

Review 2.  Primary Membranous Nephropathy.

Authors:  William G Couser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

Review 3.  Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.

Authors:  Miaomiao Chen; Xuehan Zhang; Yi Xiong; Gaosi Xu
Journal:  Int Urol Nephrol       Date:  2022-09-25       Impact factor: 2.266

4.  Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.

Authors:  Chao Li; Hang Li; Yu-Bing Wen; Xue-Mei Li; Xue-Wang Li
Journal:  BMC Nephrol       Date:  2018-12-12       Impact factor: 2.388

5.  Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.

Authors:  Christine Barrett; Lisa C Willcocks; Rachel B Jones; Ruth M Tarzi; Robert B Henderson; Gengqian Cai; Sophie I Gisbert; Alexandra S Belson; Caroline O Savage
Journal:  Nephrol Dial Transplant       Date:  2020-04-01       Impact factor: 5.992

6.  Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.

Authors:  Chunying Xiao; Yong Liu; Xinpeng Zhang; Lin Luo; Xiaoying Li; Tingting Wang; Zhe Tian; Xiaosong Qin; Jianhua Liu
Journal:  J Clin Lab Anal       Date:  2020-05-24       Impact factor: 2.352

7.  Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.

Authors:  Gabriel Stefan; Simona Stancu; Adrian Zugravu; Otilia Popa; Dalia Zubidat; Nicoleta Petre; Gabriel Mircescu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

8.  Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy.

Authors:  R Ramachandran; A K Yadav; V Kumar; N Inamdar; R Nada; K L Gupta; V Jha
Journal:  Kidney Int Rep       Date:  2017-09-14

9.  Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study.

Authors:  Peihong Yin; Junxian Wang; Wenyi Liang; Linda Zhan; Yuanhao Liu; Jian Lin; Xiaohong Chen; Yingqin He; Hongyun Jian; Zhibin Xie; Xiaofan Tan; Qing Ye; Fengxian Huang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

10.  Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy.

Authors:  Elias Jatem-Escalante; María Luisa Martín-Conde; Esther Gràcia-Lavedan; Ivan D Benítez; Jorge Gonzalez; Laura Colás; Alicia Garcia-Carrasco; Cristina Martínez; Alfons Segarra-Medrano
Journal:  Clin Kidney J       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.